Neumora Therapeutics Inc [NMRA] stock prices are up 3.07% to $3.02 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NMRA shares have gain 14.83% over the last week, with a monthly amount glided 69.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on October 27, 2025, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, JP Morgan downgraded its rating to Underweight on September 16, 2025. On April 02, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $1 on the stock. William Blair downgraded its rating to a Mkt Perform. Stifel downgraded its rating to a Hold and reduced its price target to $2 on March 07, 2025. Guggenheim downgraded its rating to Neutral for this stock on March 07, 2025. In a note dated January 02, 2025, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $29 to $4.
The stock price of Neumora Therapeutics Inc [NMRA] has been fluctuating between $0.61 and $14.09 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $3.02 at the most recent close of the market. An investor can expect a potential return of 164.9% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.13, Equity is -0.99 and Total Capital is -1.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.81 points at the first support level, and at 2.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.24, and for the 2nd resistance point, it is at 3.46.
Ratios To Look Out For
It’s worth pointing out that Neumora Therapeutics Inc [NASDAQ:NMRA]’s Current Ratio is 10.54. In addition, the Quick Ratio stands at 10.54 and the Cash Ratio stands at 5.89.
Transactions by insiders
Recent insider trading involved Burow Kristina, Director, that happened on Oct 27 ’25 when 1.92 million shares were purchased. 10% Owner, ARCH Venture Partners XII, LLC completed a deal on Oct 27 ’25 to buy 1.92 million shares. Meanwhile, 10% Owner ARCH Venture Partners X, LLC bought 1.92 million shares on Oct 27 ’25.
